Fig. 5: RGMa disrupts BCB through Neogenin receptor.
From: The liver and muscle secreted HFE2-protein maintains central nervous system blood vessel integrity
a HFE2 blocks RGMa-interaction with Neogenin. Competitive binding between RGMa and HFE2 on Neogenin-AP. RGMa blocks binding to HFE2 and HFE2 to RGMa (mean ± s.e.m.; unpaired two-tail t-test; replicates n = 3). b Expression of Neogenin in the cerebral endothelial cells (CD31) in mice (scale bar, 10 µm) and vascular structure in human (arrows; scale bar, 30 µm). This pattern was observed in sections from 3 mouse brains and 2 human patients. c Representative 3D light-sheet images of NeoΔTie2-creERT mice treated (TAM + ) and untreated (TAM-) with Tamoxifen before subsequent RGMa treatment (scale bars, 400 µm) and quantification (mean ± s.e.m.; unpaired two-tail t-test; TAM- & PBS n = 4, TAM- & RGMa n = 4, TAM+ & RGMa n = 4). d Representative in-vivo multiphoton images at 45 mins time-point (scale bar, 50 µm) and time-series quantification (mean ± s.e.m.; two-way ANOVA with post-hoc Bonferroni test; TAM- & PBS n = 4, TAM- & RGMa n = 4, TAM+ & RGMa n = 4). Representative confocal images of fibrinogen staining in the brain (e; scale bar, 50 µm) and quantification (f; mean ± s.e.m.; unpaired two-tail t-test; TAM- & PBS n = 4, TAM- & RGMa n = 5, TAM+ & RGMa n = 6). *P < 0.05, **P < 0.01, ***P < 0.001. Source data are provided as a Source Data file (includes exact p-values).
